Introduction Heart failure with reduced ejection fraction (HFrEF) increases the risk of sudden
cardiac death (SCD). ESC and NICE guidelines recommend primary prevention implantable …

The use of implantable cardioverter-defibrillators (ICDs) significantly reduces the risk of
mortality in patients with heart failure with reduced ejection fraction (HFrEF). Current …

Introduction: Individuals with heart failure (HF) and severely reduced LVEF (≤ 35%) have
increased risk of SCD and qualify for primary prevention ICD implantation. Guideline …

A critical “waiting period” of~ 3 months is generally accepted in patients with
newlydiagnosed heart failure with reduced ejection fraction (HFrEF) outside the context of …

Background A prophylactic implantable cardioverter defibrillator (ICD) in patients with heart
failure and reduced left ventricular ejection fraction (HFrEF) is only indicated when left …

Patients, therapy, and evidence have evolved in leaps since 2002, when MADIT-2 1 first
demonstrated a mortality benefit from using primary prevention ICD therapy. From 1995 to …

Left ventricular reverse remodeling (LVRR) in patients with heart failure with reduced
ejection fraction (HFrEF) is a commonly encountered clinical phenomenon after treatment …

Aims International guidelines advocate an implantable cardioverter and defibrillator (ICD) in
patients with reduced left ventricular ejection fraction (LVEF) to prevent sudden death (SCD) …

Background: This study was conducted to evaluate compliance with guideline-directed
optimal medical therapy (OMT) and its association with early implantable cardioverter …

Aims Use of implantable cardioverter‐defibrillators (ICD) for primary prevention of sudden
cardiac death (SCD) in heart failure with reduced ejection fraction (HFrEF) is limited. We …